January - March 2005, Volume 1, Issue 1
General Endocrinology
This Article
Services
Google Scholar
PubMed
Acta Endocrinologica (Buc)
Serpoi G, Cucu C
Transminases are significantly increased in patients with metabolic syndrome compared with obese controls
Acta Endo (Buc) 2005, 1 (1): 19-29doi: 10.4183/aeb.2005.19
In a population of 271 obese patients admitted in our hospital from 01.01.2002 till 3.12.2003 we randomly selected 155 subjects for this study. The patients were divided according to the ATPIII diagnostic criteria for metabolic syndrome in 2 groups: those with\r\n3 or more criteria (n= 72, 46.4% = the study group, metabolic syndrome) and those with 2 or fewer criteria (= the control group - obesity without metabolic syndrome). The patients in the study group had significantly increased plasmatic levels of transaminases when compared with the control group [TGP 44.9?3.1 versus 26.4?1.3 (p<0.001), TGO 35.5?2.3 versus 22.7?0.9 (p< 0.001), GGT 55.1?4.6 versus 25.2?1.5 (p< 0.001)]. Patients in the study group had significantly more frequently serum levels of transaminases above the upper limit of the normal range (hepatocytolytic syndrome) - TGP and GGT increased in 30%, respectively 45%, but in only 5% of subjects with obesity but no metabolic syndrome. We conclude that hepatic involvement is more frequent and more important in obesity + metabolic syndrome. Accounting for the actual epidemic of obesity and metabolic syndrome we estimated a related increment of associated hepatic involvement.
Keywords: metabolic syndrome, obesity, transaminases, liver disease
Correspondence: Correspondence to: Gheorghe Serpoi, Universitary Hospital CFR 2, Marasti street, 63-65, Bucharest,\r\ntel: 40.744669357
References:
1. Ezzati M, Lopez AD, Rodgers A, Van der Hoorn S, Murray CJL, and the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-60.
[CrossRef]
2. Van Steenbergen W, Lanckmans S. Liver disturbances in obesity and diabetes mellitus. Int J Obes Relat Metab Disord. 1995; 19 Suppl 3:S27-36.
3. Festi D, Colecchia A, Sacco T, Bondi M, Roda E, Marchesini G. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev 2004; 5(1):27-42.
[CrossRef]
4. Torgerson JS, Lindroos AK, Sjostrom CD, Olsson R, Lissner L, Sjostrom L. Are elevated aminotransferases and decreased bilirubin additional characteristics of the metabolic syndrome? Obes Res 1997; 5(2):105-14.
5. Cortez-Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr 1999; 18(6):353-8.
[CrossRef]
6. Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 2002; 16(4):703-16.
[CrossRef]
7. Friis-Liby I, Aldenborg F, Jerlstad P, Rundstrom K, Bjornsson E. High prevalence of metabolic complications in patients with non-alcoholic fatty liver disease. Scand J Gastroenterol 2004; 39(9):864-9.
[CrossRef]
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detecti
9. Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, Antonini TM, Alessandri C. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol 2003;18(5):588-94.
[CrossRef]
10. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990; 12(5):1106-10.
[CrossRef]
11. Papadia FS, Marinari GM, Camerini G, Murelli F, Carlini F, Stabilini C, Scopinaro N. Liver damage in severely obese patients: a clinical-biochemical-morphologic study on 1,000 liver biopsies. Obes Surg 2004; 14(7):952-8.
[CrossRef]
12. Guzzaloni G, Grugni G, Minocci A, Moro D, Morabito F. Liver steatosis in juvenile obesity: correlations with lipid profile, hepatic biochemical parameters and glycemic and insulinemic responses to an oral glucose tolerance test. Int J Obes Relat Metab D
[CrossRef]
13. Chan DF, Li AM, Chu WC, et al. Hepatic steatosis in obese Chinese children. Int J Obes Relat Metab Disord 2004; 28(10):1257-63.
[CrossRef]
14. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification T
[CrossRef]
15. Unger RH. Lipid overload and overflow: metabolic trauma and metabolic syndrome. Trends in Endocrinol Metab 2003; 14(9):398-403.
16. Weiss R, Dziura J, Burgert TS, et al. Obesity and the metabolic syndrome in children and adolescents. NEJM 2004; 350(23):2362-74.
[CrossRef]
17. Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. Rev Gastroenterol Disord 2002; 2(1):11-19.
18. Angulo P. Nonalcoholic fattty liver disease. NEJM 2002; 346(16):1221-31.
[CrossRef]
19. Marceau P, Biron S, Hould F-S, Marceau S, Simard S, Thung SN, Kral JG. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84:1513-17.
[CrossRef]
20. Lee DH, Silventoinen K, Jacobs DR, Jousilahti P, Tuomileto J. g-Glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 2004; 89(11):5410-14.
[CrossRef]
21. LeeDH, Jacobs DR, Gross M, et al. g-Glutamyltransferase, is a predictor of incident diabetes and hypertension: the CARDIA study. Clin Chem 2003; 49:1358-66.
[CrossRef]
22. Custro N, Carrocio A, Ganci A, Scafdi V, et al. Glycemic homeostasis in chronic viral hepatitis and liver cirrhosis. Diabetes Metab 2001; 27:476-81.
23. LeeDH, Blomhoff R, Jacobs DR. Is serum g-glutamyltransferase a marker of oxidative stress? Free Radic Res 2004; 38:535-9.
[CrossRef]
24. Sattar N, et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic sybdrome and C-reactive protein in the West Scotland Coronary Prevention Study. Diabetes 2004; 53(11):2855-60.
[CrossRef]
25. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo- Perin P, Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology 2002; 35(
[CrossRef]
26. Garg A, Misra A. Hepatic steatosis, insulin resistance and adipose tissue disorders (Editorial). J Clin Endocrinol Metab 2002; 87(7):3019-22.
[CrossRef]
27. Cortez-Pinto H, Ermelinda Camilo M. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol 2004; 18(6):1089-1104.
28. Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, KhalilL, Turpin G, Opolon P, Poynard. Liver fibrosis in overweight patients. Gastroenterology 2000; 118:1117?1123.
[CrossRef]
29. Dixon JB, Bhathal PS, O?Brien PE.Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121(1):91-100.
[CrossRef]
30. Ioannou GN, Weiss NS, Kowdley KV, Dominitz JA. Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study. Gastroenterology 2003; 125:1053-1059.
[CrossRef]
31. Scheen AJ, Luyckx FH.Nonalcoholic steatohepatitis and insulin resistance: interface between gastroenterologists and endocrinologists. Acta Clin Belg 2003; 58(2):81-91.
Romanian Academy
The Publishing House of the Romanian Academy
